Drugs / TS23
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03001544 | Jul 2015 → Jun 2016 | brain ischemia, myocardial infarction, pulmonary embolism, thrombotic disease +1 | Translational Sciences, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05948566 | Mar 2024 → Jul 2027 expected | ischemic stroke | Translational Sciences, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05408546 | May 2023 → Aug 2026 overdue | pulmonary embolism | Translational Sciences, Inc. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-09-15 | Daiichi Sankyo | Daiichi Sankyo Signs Agreement with Translational Sciences, Inc. to Develop and Commercialize the First-In-Class Thrombus Dissolving Agent, TS23 daiichisankyo.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TS23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05948566 ↗ |
| Action | Inhibit | “TS23 is a monoclonal antibody that inactivates alpha 2-antiplasmin.” NCT03001544 ↗ |
| Modality | Monoclonal antibody | “TS23 is a monoclonal antibody that inactivates alpha 2-antiplasmin.” NCT03001544 ↗ |
| Route | Intravenous | “a single intravenous dose of TS23” NCT03001544 ↗ |